Ernexa Therapeutics Inc. ERNA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Ernexa Therapeutics Inc. (ERNA) is a healthcare company listed in the US with a market value of about $3M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.0, a 5-year average ROIC of -286%.
About Ernexa Therapeutics
Ernexa Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $26M in 2014 to $582000 in 2024, a decline of about 31.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3000% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $582000 | $68000 | $0 | — | $6M | $20M | $23M | $21M | $22M |
| Net income | -$14M | -$45M | -$22M | -$25M | -$123M | -$7M | -$2M | -$259000 | -$1M | -$3M |
| Free cash flow | -$7M | -$16M | -$20M | -$21M | -$24M | -$8M | $3M | $717000 | -$179000 | -$404000 |
| EPS (diluted) | $-2.24 | $-48.96 | $-61.19 | $-120.87 | $-848.96 | $-122.99 | $-215.98 | $-30.00 | $-134989.03 | $-461962.47 |
| Net margin | — | -7652.8% | -31864.7% | — | — | -125.7% | -10.3% | -1.1% | -5.1% | -13.1% |
| ROIC | -321.3% | -519.2% | -56.6% | -213.2% | -318.3% | -61.1% | -8.8% | 1.1% | -10.4% | -14.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Ernexa Therapeutics’s P/E ratio?
About 0.0, based on the last twelve months of diluted earnings per share.
Does Ernexa Therapeutics pay a dividend?
Not currently.
Is Ernexa Therapeutics a good stock to buy?
We do not give buy or sell advice. Ernexa Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.